

Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 risk in the HVTN 505 HIV vaccine trial

Li et al

Supplementary Figure




Figure S1. Associations of the *FCGR3B* SNP FCGR3B-5'utr222-G/A (rs34085961) with (A) *FCRLA* and (B) *FCGR2A* expression based on B cell expression data from (1).

1. Lappalainen T, Sammeth M, Friedlander MR, t Hoen PA, Monlong J, Rivas MA, et al. 2013. Transcriptome and genome sequencing uncovers functional variation in humans. *Nature* 501:506-11.

Supplementary Tables

Table S1. Assessment of whether and how each FcγR SNP modified the vaccine/placebo hazard ratio of HIV-1 acquisition in HVTN 505

SNP	Genotype	# Vaccinees /# Placebos	OR	95% CI	Interaction Test			
					P-value	P-value	FDR (Q-value)	P _{FWER}
CD16_01_448	GG	8::7	0.89	(0.26, 3.07)	0.860	0.477	0.758	0.995
	GT/TT	19::14	1.6	(0.72, 3.54)	0.245			
CD16_02_44 (FCGR3B-5'utr44-T/A)	TT	10::16	0.66	(0.29, 1.5)	0.317	0.033	0.178	0.408
	TA/AA	14::5	2.84	(0.98, 8.18)	0.054			
CD16_02_99 (FCGR3B-5'utr99-C/G)	CC	9::14	0.68	(0.29, 1.6)	0.375	0.032	0.178	0.408
	CG/GG	18::7	2.6	(1.06, 6.37)	0.036			
CD16_02_222 (FCGR3B-5'utr222-G/A)	GG	10::16	0.65	(0.29, 1.49)	0.308	0.023	0.178	0.297
	GA/AA	15::5	3.07	(1.07, 8.75)	0.036			
CD16_02_385	AA	8::13	0.62	(0.24, 1.59)	0.324	0.059	0.195	0.593
	AC/CC	17::8	2.25	(0.91, 5.54)	0.078			
CD16_02_425	TT	8::12	0.7	(0.27, 1.82)	0.467	0.154	0.369	0.884
	TG/GG	16::9	1.82	(0.76, 4.33)	0.176			
CD16_02_473	GG	12::14	0.84	(0.37, 1.87)	0.665	0.119	0.338	0.861
	GA/AA	14::7	2.23	(0.87, 5.75)	0.095			
CD16_09_626	TT	15::6	2.32	(0.89, 6.08)	0.087	0.132	0.338	0.873
	TG/GG	12::15	0.88	(0.4, 1.95)	0.759			
CD16_10_332	TT	23::17	1.36	(0.71, 2.61)	0.360	0.946	0.970	0.999
	TC/CC	3::3	1.27	(0.23, 7.08)	0.782			
CD16_10_885	GG	7::5	1.35	(0.39, 4.63)	0.636	0.980	0.977	0.999
	GT/TT	20::16	1.32	(0.66, 2.65)	0.429			
CD16_13_268	GG	11::11	0.77	(0.28, 2.1)	0.611	0.186	0.425	0.920
	GA/AA	16::10	2.15	(0.84, 5.49)	0.111			
CD32_04_275	CC	22::16	1.36	(0.7, 2.65)	0.368	0.885	0.942	0.999
	CT/TT	5::5	1.22	(0.33, 4.5)	0.766			
CD32_04_276	AA	21::15	1.37	(0.69, 2.72)	0.364	0.853	0.942	0.999
	AG/GG	6::6	1.21	(0.38, 3.89)	0.751			
CD32_04_604	TT	22::16	1.36	(0.7, 2.65)	0.368	0.885	0.961	0.999
	TC/CC	5::5	1.22	(0.33, 4.5)	0.766			
CD32_05_423	GG	15::14	1.14	(0.52, 2.49)	0.748	0.553	0.825	0.997
	GA/AA	12::7	1.7	(0.62, 4.65)	0.304			
CD32_06_126 (FCGR2C-intron6-126-C/T)	CC	15::17	0.94	(0.46, 1.92)	0.857	0.131	0.338	0.873
	CT/TT	11::4	2.68	(0.83, 8.62)	0.099			
CD32_06_197 (FCGR2C-intron6-197-G/A)	GG	19::9	2.33	(0.98, 5.55)	0.056	0.055	0.195	0.587
	GA/AA	7::12	0.53	(0.17, 1.6)	0.260			
CD32_06_441 (FCGR2C-exon6-441-C/T)	CC	17::20	0.86	(0.44, 1.7)	0.667	0.034	0.178	0.408
	CT/TT	9::1	9.79	(1.17, 81.78)	0.035			
CD32_06_590 (FCGR2C-intron6-590-G/A)	GG	17::20	0.86	(0.44, 1.7)	0.667	0.034	0.182	0.408
	GA/AA	9::1	9.79	(1.17, 81.78)	0.035			
CD32_07_86	GG	22::16	1.36	(0.7, 2.65)	0.368	0.885	0.970	0.999
	GA/AA	5::5	1.22	(0.33, 4.5)	0.766			
CD32_07_232	GG	9::5	2.05	(0.66, 6.37)	0.213	0.369	0.656	0.987
	GA/AA	18::16	1.12	(0.56, 2.25)	0.753			
CD32_11_395	GG	20::16	1.21	(0.61, 2.41)	0.580	0.601	0.859	0.998
	GA/AA	7::5	1.75	(0.53, 5.82)	0.359			
CD32_11_454	AA	10::12	0.88	(0.37, 2.09)	0.767	0.198	0.425	0.927
	AG/GG	17::9	1.92	(0.84, 4.41)	0.125			
CD32_12_392	GG	24::18	1.39	(0.74, 2.63)	0.309	0.689	0.901	0.999
	GA/AA	3::3	0.97	(0.18, 5.1)	0.970			
CD32_12_477	CC	9::11	0.75	(0.29, 1.93)	0.550	0.127	0.338	0.873
	CT/TT	18::10	2.04	(0.89, 4.69)	0.091			
CD32_13_258	AA	22::16	1.36	(0.7, 2.65)	0.368	0.885	0.970	0.999
	AG/GG	5::5	1.22	(0.33, 4.5)	0.766			
CD32_13_645	GG	10::12	0.91	(0.38, 2.2)	0.840	0.256	0.521	0.964
	GA/AA	17::9	1.84	(0.8, 4.24)	0.150			
CD32_14_126	CC	14::14	1.08	(0.5, 2.34)	0.838	0.422	0.705	0.990

	CT/TT	13::7	1.79	(0.69, 4.6)	0.229			
CD32_14_261	TT	20::13	1.72	(0.8, 3.68)	0.164	0.274	0.526	0.964
	TC/CC	7::8	0.77	(0.25, 2.4)	0.657			
CD32_14_352	TT	9::8	1.12	(0.4, 3.12)	0.823	0.694	0.901	0.999
	TG/GG	18::13	1.46	(0.68, 3.11)	0.328			
CD32_14_447	GG	17::15	1.23	(0.58, 2.61)	0.591	0.742	0.926	0.999
	GT/TT	10::6	1.56	(0.51, 4.76)	0.437			
CD32_15_403	CC	15::18	0.88	(0.43, 1.78)	0.719	0.045	0.182	0.508
(FCGR2C-intron15-403-C/T)	CT/TT	12::3	3.92	(1.08, 14.16)	0.037			
CD32_15_433	GG	13::17	0.82	(0.39, 1.73)	0.601	0.042	0.182	0.487
(FCGR2C-intron15-433-G/A)	GA/AA	14::4	3.33	(1.08, 10.29)	0.036			

Table S2. Assessment of whether and how each FcγR SNP modified the inverse correlation of Env-specific CD8 with HIV-1 infection risk in HVTN 505 reported by Janes et al. (1).

SNP	Genotype	# case /#controls	OR	95% CI	P-value	Interaction Test		
						P-value	FDR(Q-value)	P _{FWER}
CD16_01_448	GG	6/55	0.47	(0.17, 1.3)	0.148	0.255	0.655	0.982
	GT/TT	19/70	0.22	(0.09, 0.51)	0.0005			
CD16_02_44 (FCGR3B-5'utr44-T/A)	TT	10/44	0.19	(0.06, 0.6)	0.005	0.377	0.677	0.996
	TA/AA	12/80	0.36	(0.15, 0.84)	0.018			
CD16_02_99 (FCGR3B-5'utr99-C/G)	CC	9/39	0.18	(0.05, 0.61)	0.006	0.37	0.677	0.996
	CG/GG	16/85	0.35	(0.16, 0.75)	0.008			
CD16_02_222 (FCGR3B-5'utr222-G/A)	GG	10/44	0.18	(0.05, 0.58)	0.004	0.372	0.677	0.996
	GA/AA	13/80	0.34	(0.15, 0.8)	0.013			
CD16_02_385	AA	8/39	0.16	(0.04, 0.64)	0.01	0.287	0.655	0.985
	AC/CC	15/85	0.37	(0.17, 0.78)	0.009			
CD16_02_425	TT	8/37	0.07	(0.01, 0.52)	0.009	0.109	0.544	0.826
	TG/GG	14/88	0.4	(0.19, 0.85)	0.016			
CD16_02_473	GG	10/42	0.13	(0.03, 0.55)	0.006	0.194	0.655	0.960
	GA/AA	14/83	0.38	(0.17, 0.81)	0.013			
CD16_09_626	TT	14/53	0.42	(0.2, 0.9)	0.025	0.205	0.655	0.969
	TG/GG	11/71	0.16	(0.05, 0.58)	0.005			
CD16_10_332	TT	21/99	0.32	(0.16, 0.63)	0.001	0.89	0.943	1.000
	TC/CC	3/24	0.28	(0.05, 1.68)	0.163			
CD16_10_885	GG	5/35	0.22	(0.05, 1)	0.049	0.632	0.843	0.999
	GT/TT	20/90	0.33	(0.16, 0.66)	0.002			
CD16_13_268	GG	9/73	0.48	(0.21, 1.09)	0.078	0.151	0.655	0.922
	GA/AA	16/52	0.19	(0.07, 0.5)	0.001			
CD32_04_275	CC	20/102	0.39	(0.21, 0.73)	0.003	0.058	0.354	0.626
	CT/TT	5/23	0.01	(0, 0.41)	0.016			
CD32_04_276	AA	19/102	0.4	(0.21, 0.75)	0.004	0.05	0.354	0.573
	AG/GG	6/23	0.01	(0, 0.37)	0.014			
CD32_04_604	TT	20/102	0.39	(0.21, 0.73)	0.003	0.058	0.425	0.626
	TC/CC	5/23	0.01	(0, 0.41)	0.016			
CD32_05_423	GG	14/84	0.37	(0.16, 0.82)	0.014	0.51	0.787	0.999
	GA/AA	11/41	0.23	(0.08, 0.66)	0.006			
CD32_06_126 (FCGR2C-intron6-126-C/T)	CC	14/69	0.3	(0.13, 0.67)	0.003	0.941	0.958	1.000
	CT/TT	10/56	0.31	(0.11, 0.88)	0.028			
CD32_06_197 (FCGR2C-intron6-197-G/A)	GG	17/73	0.29	(0.13, 0.65)	0.003	0.839	0.938	1.000
	GA/AA	7/52	0.33	(0.12, 0.95)	0.04			
CD32_06_441 (FCGR2C-exon6-441-C/T)	CC	16/82	0.24	(0.1, 0.55)	0.001	0.313	0.655	0.989
	CT/TT	8/43	0.47	(0.17, 1.31)	0.148			
CD32_06_590 (FCGR2C-intron6-590-G/A)	GG	16/82	0.24	(0.1, 0.55)	0.001	0.313	0.677	0.989
	GA/AA	8/43	0.47	(0.17, 1.31)	0.148			
CD32_07_86	GG	20/104	0.38	(0.2, 0.72)	0.003	0.057	0.354	0.626
	GA/AA	5/21	0.01	(0, 0.41)	0.016			
CD32_07_232	GG	9/37	0.33	(0.13, 0.84)	0.021	0.812	0.938	1.000
	GA/AA	16/88	0.28	(0.12, 0.67)	0.004			
CD32_11_395	GG	18/84	0.34	(0.17, 0.69)	0.003	0.537	0.787	0.999
	GA/AA	7/40	0.21	(0.05, 0.87)	0.031			
CD32_11_454	AA	10/38	0.21	(0.06, 0.68)	0.01	0.453	0.764	0.999
	AG/GG	15/86	0.36	(0.17, 0.77)	0.008			
CD32_12_392	GG	22/105	0.29	(0.15, 0.59)	0.001	0.862	0.943	1.000
	GA/AA	3/20	0.34	(0.07, 1.71)	0.191			
CD32_12_477	CC	8/60	0.38	(0.14, 1.07)	0.068	0.52	0.787	0.999
	CT/TT	17/65	0.25	(0.11, 0.57)	0.001			
CD32_13_258	AA	20/103	0.39	(0.21, 0.73)	0.003	0.056	0.354	0.618
	AG/GG	5/21	0.01	(0, 0.4)	0.015			
CD32_13_645	GG	9/60	0.5	(0.2, 1.3)	0.155	0.218	0.655	0.972
	GA/AA	16/64	0.22	(0.1, 0.53)	0.001			
CD32_14_126	CC	13/77	0.35	(0.16, 0.79)	0.011	0.575	0.805	0.999
	CT/TT	12/46	0.24	(0.09, 0.69)	0.008			

CD32_14_261	TT	18/89	0.23	(0.1, 0.53)	0.001	0.269	0.655	0.983
	TC/CC	7/34	0.47	(0.18, 1.22)	0.12			
CD32_14_352	TT	8/48	0.48	(0.19, 1.23)	0.125	0.237	0.65	0.977
	TG/GG	17/75	0.22	(0.09, 0.53)	0.001			
CD32_14_447	GG	16/91	0.28	(0.12, 0.64)	0.002	0.729	0.91	1.000
	GT/TT	9/32	0.36	(0.13, 0.99)	0.047			
CD32_15_403 (FCGR2C-intron15-403-C/T)	CC	14/78	0.28	(0.12, 0.63)	0.002	0.746	0.91	1.000
	CT/TT	11/47	0.34	(0.13, 0.93)	0.035			
CD32_15_433 (FCGR2C-intron15-433-G/A)	GG	12/75	0.29	(0.12, 0.69)	0.005	0.977	0.98	1.000
	GA/AA	13/50	0.3	(0.11, 0.8)	0.016			

1. Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, et al. 2017. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. J Infect Dis 215:1376-1385.

Table S3. Assessment of whether and how each FcγR SNP modified the inverse correlation of Env-specific IgG response with HIV-1 acquisition risk in HVTN 505 reported by Fong and Shen et al. (2).

SNP	Genotype	# case /#controls	OR	95% CI	P-value	Interaction Test		
						P-value	FDR(Q-value)	P _{FWER}
CD16_01_448	GG	6/55	0.83	(0.29, 2.39)	0.733	0.744	0.809	0.994
	GT/TT	19/70	0.68	(0.4, 1.17)	0.167			
CD16_02_44 (FCGR3B-5'utr44-T/A)	TT	10/44	0.38	(0.16, 0.93)	0.034	0.035	0.215	0.415
	TA/AA	12/80	1.41	(0.62, 3.17)	0.412			
CD16_02_99 (FCGR3B-5'utr99-C/G)	CC	9/39	0.3	(0.1, 0.88)	0.028	0.028	0.215	0.347
	CG/GG	16/85	1.27	(0.64, 2.53)	0.502			
CD16_02_222 (FCGR3B-5'utr222-G/A)	GG	10/44	0.37	(0.15, 0.93)	0.034	0.044	0.215	0.489
	GA/AA	13/80	1.28	(0.59, 2.77)	0.532			
CD16_02_385	AA	8/39	0.35	(0.13, 0.92)	0.034	0.047	0.215	0.500
	AC/CC	15/85	1.16	(0.57, 2.36)	0.672			
CD16_02_425	TT	8/37	0.33	(0.12, 0.95)	0.040	0.040	0.215	0.454
	TG/GG	14/88	1.28	(0.61, 2.72)	0.512			
CD16_02_473	GG	10/42	0.41	(0.17, 1)	0.051	0.048	0.215	0.489
	GA/AA	14/83	1.34	(0.63, 2.84)	0.449			
CD16_09_626	TT	14/53	0.7	(0.36, 1.37)	0.300	0.986	0.986	0.994
	TG/GG	11/71	0.71	(0.38, 1.34)	0.289			
CD16_10_332	TT	21/99	0.61	(0.36, 1.01)	0.056	0.206	0.506	0.943
	TC/CC	3/24	1.51	(0.4, 5.72)	0.545			
CD16_10_885	GG	5/35	0.91	(0.19, 4.38)	0.902	0.778	0.817	0.994
	GT/TT	20/90	0.72	(0.45, 1.15)	0.166			
CD16_13_268	GG	9/73	0.79	(0.36, 1.72)	0.551	0.712	0.802	0.994
	GA/AA	16/52	0.65	(0.35, 1.23)	0.185			
CD32_04_275	CC	20/102	0.85	(0.46, 1.57)	0.600	0.448	0.639	0.992
	CT/TT	5/23	0.57	(0.25, 1.29)	0.177			
CD32_04_276	AA	19/102	0.89	(0.47, 1.66)	0.704	0.431	0.639	0.990
	AG/GG	6/23	0.59	(0.27, 1.3)	0.191			
CD32_04_604	TT	20/102	0.85	(0.46, 1.57)	0.600	0.448	0.639	0.992
	TC/CC	5/23	0.57	(0.25, 1.29)	0.177			
CD32_05_423	GG	14/84	1.14	(0.56, 2.3)	0.717	0.054	0.215	0.516
	GA/AA	11/41	0.4	(0.19, 0.92)	0.031			
CD32_06_126 (FCGR2C-intron6-126-C/T)	CC	14/69	0.55	(0.29, 1.03)	0.063	0.111	0.376	0.785
	CT/TT	10/56	1.3	(0.54, 3.11)	0.553			
CD32_06_197 (FCGR2C-intron6-197-G/A)	GG	17/73	0.81	(0.48, 1.38)	0.444	0.511	0.665	0.994
	GA/AA	7/52	0.57	(0.23, 1.43)	0.232			
CD32_06_441 (FCGR2C-exon6-441-C/T)	CC	16/82	0.6	(0.35, 1.05)	0.075	0.162	0.461	0.900
	CT/TT	8/43	1.37	(0.49, 3.78)	0.546			
CD32_06_590 (FCGR2C-intron6-590-G/A)	GG	16/82	0.6	(0.35, 1.05)	0.075	0.162	0.497	0.900
	GA/AA	8/43	1.37	(0.49, 3.78)	0.546			
CD32_07_86	GG	20/104	0.85	(0.46, 1.57)	0.598	0.454	0.639	0.992
	GA/AA	5/21	0.57	(0.25, 1.29)	0.180			
CD32_07_232	GG	9/37	0.47	(0.17, 1.35)	0.163	0.370	0.639	0.984
	GA/AA	16/88	0.8	(0.48, 1.34)	0.399			
CD32_11_395	GG	18/84	0.64	(0.36, 1.14)	0.129	0.516	0.665	0.994
	GA/AA	7/40	0.89	(0.4, 1.99)	0.777			
CD32_11_454	AA	10/38	0.55	(0.26, 1.18)	0.125	0.299	0.583	0.974
	AG/GG	15/86	0.93	(0.48, 1.8)	0.835			
CD32_12_392	GG	22/105	0.69	(0.42, 1.14)	0.148	0.648	0.761	0.994
	GA/AA	3/20	0.92	(0.29, 2.91)	0.892			
CD32_12_477	CC	8/60	1.15	(0.4, 3.33)	0.791	0.291	0.583	0.974
	CT/TT	17/65	0.6	(0.33, 1.08)	0.089			
CD32_13_258	AA	20/103	0.85	(0.46, 1.57)	0.601	0.459	0.639	0.992
	AG/GG	5/21	0.58	(0.26, 1.3)	0.185			
CD32_13_645	GG	9/60	1.66	(0.6, 4.63)	0.329	0.036	0.215	0.416
	GA/AA	16/64	0.42	(0.2, 0.88)	0.021			
CD32_14_126	CC	13/77	0.93	(0.45, 1.92)	0.851	0.186	0.498	0.932
	CT/TT	12/46	0.47	(0.22, 1)	0.049			

CD32_14_261	TT	18/89	0.62	(0.35, 1.1)	0.099	0.591	0.723	0.994
	TC/CC	7/34	0.84	(0.32, 2.17)	0.713			
CD32_14_352	TT	8/48	1.08	(0.37, 3.16)	0.895	0.323	0.596	0.976
	TG/GG	17/75	0.59	(0.33, 1.04)	0.067			
CD32_14_447	GG	16/91	0.89	(0.46, 1.73)	0.732	0.224	0.506	0.951
	GT/TT	9/32	0.48	(0.22, 1.05)	0.065			
CD32_15_403 (FCGR2C-intron15-403-C/T)	CC	14/78	0.59	(0.34, 1.04)	0.069	0.230	0.506	0.951
	CT/TT	11/47	1.11	(0.46, 2.67)	0.812			
CD32_15_433 (FCGR2C-intron15-433-G/A)	GG	12/75	0.52	(0.28, 0.96)	0.036	0.083	0.308	0.683
	GA/AA	13/50	1.29	(0.56, 3.01)	0.551			

- Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, et al. 2018. Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. *J Infect Dis* 217:1280-1288.

Table S4. Assessment of whether and how each FcγR SNP modified the correlation of IgG and Env-specific CD8+ PFS (high or median IgG or CD8 vs. low on both IgG and CD8) with the risk of HIV-1 acquisition in HVTN 505 (2).

SNP	Genotype	# case /#controls	OR	95% CI	P-value	Interaction Test		
						P-value	FDR (Q-value)	P _{FWER}
CD16_01_448	GG	6/55	0.21	(0.03, 1.38)	0.104	0.338	0.290	0.845
	GT/TT	19/70	0.06	(0.01, 0.26)	0.0001			
CD16_02_44 (FCGR3B-5'utr44-T/A)	TT	10/44	0.02	(0, 0.15)	0.0002	0.044	0.094	0.233
	TA/AA	12/80	0.24	(0.06, 0.99)	0.049			
CD16_02_99 (FCGR3B-5'utr99-T/A)	CC	9/39	0.01	(0, 0.15)	0.001	0.041	0.094	0.215
	CG/GG	16/85	0.22	(0.06, 0.78)	0.019			
CD16_02_222 (FCGR3B-5'utr222-T/A)	GG	10/44	0.02	(0, 0.14)	0.0002	0.051	0.094	0.275
	GA/AA	13/80	0.21	(0.05, 0.8)	0.023			
CD16_02_385	AA	8/39	0.02	(0, 0.21)	0.001	0.143	0.159	0.641
	AC/CC	15/85	0.16	(0.04, 0.58)	0.005			
CD16_02_425 (FCGR3B-5'utr425-T/G)	TT	8/37	0.01	(0, 0.11)	0.0005	0.027	0.094	0.142
	TG/GG	14/88	0.22	(0.06, 0.83)	0.025			
CD16_02_473 (FCGR3B-5'utr473-G/A)	GG	10/42	0.02	(0, 0.16)	0.0002	0.051	0.094	0.262
	GA/AA	14/83	0.23	(0.06, 0.88)	0.032			
CD16_09_626	TT	14/53	0.13	(0.03, 0.58)	0.008	0.778	0.539	0.863
	TG/GG	11/71	0.09	(0.02, 0.42)	0.002			
CD16_10_332	TT	21/99	0.09	(0.03, 0.29)	0.0001	0.464	0.338	0.863
	TC/CC	3/24	0.28	(0.02, 4.41)	0.363			
CD16_10_885	GG	5/35	0.11	(0.01, 1.03)	0.053	0.94	0.893	0.863
	GT/TT	20/90	0.12	(0.04, 0.38)	0.0003			
CD16_13_268	GG	9/73	0.17	(0.04, 0.85)	0.031	0.42	0.328	0.863
	GA/AA	16/52	0.07	(0.01, 0.33)	0.001			
CD32_04_275	CC	20/102	0.17	(0.05, 0.54)	0.003	0.157	0.159	0.647
	CT/TT	5/23	0.02	(0, 0.31)	0.005			
CD32_04_276	AA	19/102	0.2	(0.06, 0.66)	0.008	0.087	0.124	0.435
	AG/GG	6/23	0.02	(0, 0.23)	0.002			
CD32_04_604	TT	20/102	0.17	(0.05, 0.54)	0.003	0.157	0.159	0.647
	TC/CC	5/23	0.02	(0, 0.31)	0.005			
CD32_05_423	GG	14/84	0.23	(0.06, 0.84)	0.027	0.07	0.119	0.360
	GA/AA	11/41	0.02	(0, 0.18)	0.0005			
CD32_06_126 (FCGR2C-intron6-126-C/T)	CC	14/69	0.09	(0.02, 0.36)	0.001	0.38	0.290	0.856
	CT/TT	10/56	0.26	(0.04, 1.6)	0.145			
CD32_06_197 (FCGR2C-intron6-197-G/A)	GG	17/73	0.08	(0.02, 0.34)	0.001	0.359	0.290	0.856
	GA/AA	7/52	0.24	(0.04, 1.39)	0.110			
CD32_06_441 (FCGR2C-exon6-441-C/T)	CC	16/82	0.08	(0.02, 0.28)	0.0001	0.137	0.159	0.612
	CT/TT	8/43	0.51	(0.06, 4.08)	0.523			
CD32_06_590 (FCGR2C-intron6-590-G/A)	GG	16/82	0.08	(0.02, 0.28)	0.000	0.137	0.159	0.612
	GA/AA	8/43	0.51	(0.06, 4.08)	0.523			
CD32_07_86	GG	20/104	0.17	(0.05, 0.53)	0.002	0.173	0.159	0.678
	GA/AA	5/21	0.02	(0, 0.34)	0.006			
CD32_07_232	GG	9/37	0.06	(0.01, 0.42)	0.005	0.442	0.336	0.863
	GA/AA	16/88	0.15	(0.04, 0.53)	0.003			
CD32_11_395	GG	18/84	0.09	(0.02, 0.33)	0.0003	0.651	0.465	0.863
	GA/AA	7/40	0.15	(0.02, 0.97)	0.046			
CD32_11_454	AA	10/38	0.08	(0.01, 0.41)	0.003	0.489	0.353	0.863
	AG/GG	15/86	0.17	(0.04, 0.65)	0.010			
CD32_12_392	GG	22/105	0.12	(0.04, 0.38)	0.0002	0.733	0.519	0.863
	GA/AA	3/20	0.07	(0, 1.84)	0.110			
CD32_12_477	CC	8/60	0.32	(0.05, 1.82)	0.197	0.134	0.159	0.612
	CT/TT	17/65	0.05	(0.01, 0.23)	0.0001			
CD32_13_258	AA	20/103	0.17	(0.05, 0.54)	0.003	0.169	0.159	0.670
	AG/GG	5/21	0.02	(0, 0.33)	0.006			
CD32_13_645	GG	9/60	0.47	(0.08, 2.69)	0.393	0.044	0.094	0.233
	GA/AA	16/64	0.03	(0.01, 0.18)	0.0001			
CD32_14_126	CC	13/77	0.17	(0.04, 0.65)	0.010	0.272	0.253	0.810

	CT/TT	12/46	0.05	(0.01, 0.29)	0.001			
CD32_14_261	TT	18/89	0.07	(0.02, 0.28)	0.0001	0.289	0.260	0.812
	TC/CC	7/34	0.27	(0.04, 1.91)	0.191			
CD32_14_352	TT	8/48	0.16	(0.03, 0.98)	0.048	0.609	0.445	0.863
	TG/GG	17/75	0.09	(0.02, 0.33)	0.0003			
CD32_14_447	GG	16/91	0.16	(0.05, 0.57)	0.004	0.238	0.227	0.776
	GT/TT	9/32	0.04	(0, 0.31)	0.003			
CD32_15_403 (FCGR2C-intron15-403-C/T)	CC	14/78	0.08	(0.02, 0.3)	0.0002	0.362	0.290	0.856
	CT/TT	11/47	0.21	(0.04, 1.14)	0.071			
CD32_15_433 (FCGR2C-intron15-433-G/A)	GG	12/75	0.04	(0.01, 0.2)	0.0001	0.084	0.124	0.423
	GA/AA	13/50	0.31	(0.06, 1.55)	0.155			

- Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, et al. 2018. Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. *J Infect Dis* 217:1280-1288.

Table S5. List of significant eQTLs for the SNPs identified from this analysis of FcyR SNPs in HVTN 505 samples

Table S6. The detailed list of SNPs in high LD with the SNPs identified from this analysis of FcyR SNPs in HVTN 505 samples

Table S7. Summary of predicted consequences for SNPs in high LD with the SNPs identified from this analysis of FcyR SNPs in HVTN 505 samples